Posts

Ipsen and Genfit Receive Accelerated FDA Nod for Liver Disorder Drug

Ipsen and Genfit Receive Accelerated FDA Nod for Liver ...

Jun 15, 2024

Initially thought of as a potential game-changer for metabolic-associated steato...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 Trial Results for Loqtorzi Show Positive Result...

Jun 15, 2024

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show ...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Du...

Jun 15, 2024

Pfizer’s gene therapy for Duchenne muscular dystrophy failed to improve motor fu...

NPX-267 by NextPoint Therapeutics for Prostate Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Prostate Cancer: ...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Endometrial Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Endometrial Cance...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Cervical Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Cervical Cancer: ...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Renal Cell Carcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Renal Cell Carcin...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Osteosarcoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Osteosarcoma: Lik...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Non-Small Cell Lu...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Transitional Cell...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval

PF-07960613 by Pfizer for Respiratory Syncytial Virus (...

Jun 14, 2024

PF-07960613 is under clinical development by Pfizer and currently in Phase II fo...

NPX-267 by NextPoint Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Triple-Negative B...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

A conservation market could incentivize global ocean protection

A conservation market could incentivize global ocean pr...

Jun 14, 2024

(Santa Barbara, Calif.) — The countries of the world agreed: Our planet needs mo...

Can engineered plants help make baby formula as nutritious as breast milk?

Can engineered plants help make baby formula as nutriti...

Jun 14, 2024

Worldwide, a majority of babies — approximately 75% — drink infant formula in th...

UTA awards more than $130,000 to spark new research

UTA awards more than $130,000 to spark new research

Jun 14, 2024

The Office of the Vice President for Research and Innovation at The University o...